Physician profile
Ravi Bhalla
NPI 1174512263
$4,948.23
in general payments reported to CMS, 2019-2025
26 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.98 · 2022: $496 · 2023: $916 · 2024: $1,210 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Education: $81.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.45 |
| Education | $81.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,991.99 | 2022-2025 | Rinvoq, Humira, Skyrizi |
| Amgen INC. | $1,370.44 | 2021-2025 | Enbrel, Krystexxa, Otezla |
| Ucb, INC. | $324.23 | 2024-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $177.91 | 2022-2025 | Benlysta |
| Medtronic, INC. | $130.43 | 2025 | Symplicity G3 |
| Pfizer INC. | $115.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $109.42 | 2022-2025 | Enhertu, Saphnelo |
| Aurinia Pharma U.S., INC. | $92.98 | 2023-2025 | Lupkynis |
| Radius Health, INC. | $79.50 | 2024-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $77.48 | 2024 | Orencia |
| Abbott Laboratories | $70.18 | 2023-2025 | Proclaim, Eterna |
| Janssen Biotech, INC. | $68.82 | 2022-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $42.12 | 2025 | |
| Sobi, INC | $38.50 | 2024 | |
| Genentech USA, INC. | $37.01 | 2025 | Actemra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $34.73 | 2022-2023 | Krystexxa |
| Actelion Pharmaceuticals US, INC. | $30.31 | 2025 | Opsumit |
| Tonix Medicines, INC. | $24.25 | 2025 | Tonmya |
| Organon LLC | $20.56 | 2023 | Hadlima |
| Mallinckrodt Hospital Products INC. | $19.16 | 2025 | Acthar |
| Tersera Therapeutics LLC | $18.09 | 2021 | |
| Genzyme Corporation | $17.05 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2025 | Jascayd |
| Ani Pharmaceuticals, INC. | $14.78 | 2023 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $14.24 | 2024 | |
| Sandoz INC. | $13.68 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.